ESMO Open
Cancer Horizons

Check for updates

Report from the ESMO 2018 presidential symposium—Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE

Chris Parker[1,2]

To cite: Parker C. Report from the ESMO 2018 presidential symposium—Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE. *ESMO Open* 2018;**3**:e000451. doi:10.1136/esmoopen-2018-000451

Received 4 October 2018
Accepted 4 October 2018

© Author (s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.

[1]The Royal Marsden NHS Foundation Trust, Sutton, UK
[2]The Institute of Cancer Research, Sutton, UK

Correspondence to
Dr Chris Parker; chris.parker@rmh.nhs.uk

Click here to listen to the Podcast

Radiotherapy to the primary tumour has been much discussed as a possible intervention in patients with newly diagnosed metastatic prostate cancer. Results of the STAMPEDE trial indicate that overall no survival advantage can be achieved by the addition of radiotherapy. However, patients with low volume, oligometastatic disease were shown to benefit in a predefined subgroup analysis. In the current podcast Dr. Parker provides insight on the practice changing impact of the STAMPEDE trial and gives an outlook what is next on the horizon in metastatic prostate cancer therapy.

Competing interests None declared.

Patient consent Not required.

Provenance and peer review Commissioned; internally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0